CN107106565A - Btk抑制剂组合和给药方案 - Google Patents

Btk抑制剂组合和给药方案 Download PDF

Info

Publication number
CN107106565A
CN107106565A CN201580073032.7A CN201580073032A CN107106565A CN 107106565 A CN107106565 A CN 107106565A CN 201580073032 A CN201580073032 A CN 201580073032A CN 107106565 A CN107106565 A CN 107106565A
Authority
CN
China
Prior art keywords
cell
combination
cast
combination medicine
feeding scheme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580073032.7A
Other languages
English (en)
Chinese (zh)
Inventor
萨曼莎·M·亚格洛斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Publication of CN107106565A publication Critical patent/CN107106565A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580073032.7A 2014-12-23 2015-12-22 Btk抑制剂组合和给药方案 Pending CN107106565A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462096284P 2014-12-23 2014-12-23
US62/096,284 2014-12-23
PCT/US2015/067504 WO2016106381A1 (en) 2014-12-23 2015-12-22 Btk inhibitor combinations and dosing regimen

Publications (1)

Publication Number Publication Date
CN107106565A true CN107106565A (zh) 2017-08-29

Family

ID=56151542

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580073032.7A Pending CN107106565A (zh) 2014-12-23 2015-12-22 Btk抑制剂组合和给药方案

Country Status (10)

Country Link
US (1) US20170360796A1 (cg-RX-API-DMAC7.html)
EP (1) EP3236968A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018503610A (cg-RX-API-DMAC7.html)
CN (1) CN107106565A (cg-RX-API-DMAC7.html)
AU (1) AU2015369665A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017013580A2 (cg-RX-API-DMAC7.html)
CA (1) CA2970043A1 (cg-RX-API-DMAC7.html)
HK (1) HK1245153A1 (cg-RX-API-DMAC7.html)
MX (1) MX2017008486A (cg-RX-API-DMAC7.html)
WO (1) WO2016106381A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112165945A (zh) * 2017-10-27 2021-01-01 浙江导明医药科技有限公司 治疗淋巴样恶性疾病之方法
TWI870465B (zh) * 2019-10-04 2025-01-21 日商中外製藥股份有限公司 抑制具奧比妥珠單株抗體耐受性的cd20陽性癌之細胞增殖的藥劑,及其相關之醫藥組成物、醫藥、製造、抑制細胞增殖的方法、治療方法、ii型抗cd20抗體、化合物及其組合、增強劑以及誘導劑

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
EP3493808A4 (en) * 2016-08-19 2020-04-01 Cipla Limited PHARMACEUTICAL COMPOSITIONS OF IBRUTINIB
WO2019127008A1 (zh) * 2017-12-26 2019-07-04 清华大学 一种靶向降解btk的化合物及其应用
BR112020022185A2 (pt) 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
CN120826242A (zh) * 2023-03-09 2025-10-21 浙江特瑞思药业股份有限公司 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途
WO2025249980A1 (ko) * 2024-05-31 2025-12-04 (주)노보메디슨 림프종의 예방 또는 치료를 위한 포셀티닙의 병용투여 요법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103153311A (zh) * 2010-06-03 2013-06-12 药品循环公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
CN104039325A (zh) * 2011-10-19 2014-09-10 药品循环公司 布鲁顿酪氨酸激酶(btk)抑制剂的用途
WO2014159745A1 (en) * 2013-03-14 2014-10-02 Pharmacyclics, Inc. Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
JP5960688B2 (ja) * 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規3,5−二置換−3h−[1,2,3]トリアゾロ[4,5−b]ピリジン化合物
GB201207305D0 (en) * 2012-04-26 2012-06-13 E Therapeutics Plc Therapy
ES2648094T3 (es) * 2013-06-07 2017-12-28 Rhizen Pharmaceuticals S.A. Inhibidores de PI3 cinasa delta y gamma selectivos duales
US20170231995A1 (en) * 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103153311A (zh) * 2010-06-03 2013-06-12 药品循环公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
CN104039325A (zh) * 2011-10-19 2014-09-10 药品循环公司 布鲁顿酪氨酸激酶(btk)抑制剂的用途
WO2014159745A1 (en) * 2013-03-14 2014-10-02 Pharmacyclics, Inc. Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAN A BURGER等: "Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm,phase 2 study", 《LANCET ONCOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112165945A (zh) * 2017-10-27 2021-01-01 浙江导明医药科技有限公司 治疗淋巴样恶性疾病之方法
TWI870465B (zh) * 2019-10-04 2025-01-21 日商中外製藥股份有限公司 抑制具奧比妥珠單株抗體耐受性的cd20陽性癌之細胞增殖的藥劑,及其相關之醫藥組成物、醫藥、製造、抑制細胞增殖的方法、治療方法、ii型抗cd20抗體、化合物及其組合、增強劑以及誘導劑

Also Published As

Publication number Publication date
WO2016106381A1 (en) 2016-06-30
MX2017008486A (es) 2017-09-19
EP3236968A1 (en) 2017-11-01
BR112017013580A2 (pt) 2018-04-10
CA2970043A1 (en) 2016-06-30
EP3236968A4 (en) 2018-08-01
JP2018503610A (ja) 2018-02-08
HK1245153A1 (zh) 2018-08-24
AU2015369665A1 (en) 2017-06-29
US20170360796A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
US12551448B2 (en) Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
US20170079981A1 (en) Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor
US20240238291A1 (en) Combinations for treatment of cancer
US20160022683A1 (en) Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
US20180362536A1 (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
US20170360796A1 (en) Btk inhibitor combinations and dosing regimen
US20200030330A1 (en) Bruton's tyrosine kinase inhibitor combinations and uses thereof
TW201731513A (zh) 包含btk抑制劑的配製物/組成物
WO2017040617A1 (en) Btk inhibitor combinations for treating multiple myeloma
HK40107203A (en) Pharmaceutical formulations of a bruton's tyrosine kinase inhibtor
HK1249015B (en) Pharmaceutical formulations of bruton's tyrosine kinase inhibtor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170829

WD01 Invention patent application deemed withdrawn after publication